Cargando…

Salience attribution and its relationship to cannabis-induced psychotic symptoms

BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloomfield, M. A. P., Mouchlianitis, E., Morgan, C. J. A., Freeman, T. P., Curran, H. V., Roiser, J. P., Howes, O. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122315/
https://www.ncbi.nlm.nih.gov/pubmed/27628967
http://dx.doi.org/10.1017/S0033291716002051
_version_ 1782469555164020736
author Bloomfield, M. A. P.
Mouchlianitis, E.
Morgan, C. J. A.
Freeman, T. P.
Curran, H. V.
Roiser, J. P.
Howes, O. D.
author_facet Bloomfield, M. A. P.
Mouchlianitis, E.
Morgan, C. J. A.
Freeman, T. P.
Curran, H. V.
Roiser, J. P.
Howes, O. D.
author_sort Bloomfield, M. A. P.
collection PubMed
description BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. METHOD: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K(i)(cer), was measured in 10 users and six controls with 3,4-dihydroxy-6-[(18)F]fluoro-l-phenylalanine positron emission tomography. RESULTS: There was no significant difference in aberrant salience between the groups [F(1,32) = 1.12, p = 0.30 (implicit); F(1,32) = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F(1,15) = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = −0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = −2.05, p = 0.04). CONCLUSIONS: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.
format Online
Article
Text
id pubmed-5122315
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-51223152016-11-29 Salience attribution and its relationship to cannabis-induced psychotic symptoms Bloomfield, M. A. P. Mouchlianitis, E. Morgan, C. J. A. Freeman, T. P. Curran, H. V. Roiser, J. P. Howes, O. D. Psychol Med Original Articles BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. METHOD: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K(i)(cer), was measured in 10 users and six controls with 3,4-dihydroxy-6-[(18)F]fluoro-l-phenylalanine positron emission tomography. RESULTS: There was no significant difference in aberrant salience between the groups [F(1,32) = 1.12, p = 0.30 (implicit); F(1,32) = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F(1,15) = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = −0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = −2.05, p = 0.04). CONCLUSIONS: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use. Cambridge University Press 2016-12 2016-09-15 /pmc/articles/PMC5122315/ /pubmed/27628967 http://dx.doi.org/10.1017/S0033291716002051 Text en © Cambridge University Press 2016 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Bloomfield, M. A. P.
Mouchlianitis, E.
Morgan, C. J. A.
Freeman, T. P.
Curran, H. V.
Roiser, J. P.
Howes, O. D.
Salience attribution and its relationship to cannabis-induced psychotic symptoms
title Salience attribution and its relationship to cannabis-induced psychotic symptoms
title_full Salience attribution and its relationship to cannabis-induced psychotic symptoms
title_fullStr Salience attribution and its relationship to cannabis-induced psychotic symptoms
title_full_unstemmed Salience attribution and its relationship to cannabis-induced psychotic symptoms
title_short Salience attribution and its relationship to cannabis-induced psychotic symptoms
title_sort salience attribution and its relationship to cannabis-induced psychotic symptoms
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122315/
https://www.ncbi.nlm.nih.gov/pubmed/27628967
http://dx.doi.org/10.1017/S0033291716002051
work_keys_str_mv AT bloomfieldmap salienceattributionanditsrelationshiptocannabisinducedpsychoticsymptoms
AT mouchlianitise salienceattributionanditsrelationshiptocannabisinducedpsychoticsymptoms
AT morgancja salienceattributionanditsrelationshiptocannabisinducedpsychoticsymptoms
AT freemantp salienceattributionanditsrelationshiptocannabisinducedpsychoticsymptoms
AT curranhv salienceattributionanditsrelationshiptocannabisinducedpsychoticsymptoms
AT roiserjp salienceattributionanditsrelationshiptocannabisinducedpsychoticsymptoms
AT howesod salienceattributionanditsrelationshiptocannabisinducedpsychoticsymptoms